STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of...
Hence then, the article about first patient enrolled in new study assessing early prediction of flares in atopic dermatitis by castle biosciences in collaboration with scibase was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase )
Also on site :
- Here’s What Jack Schlossberg Had to Say About Madonna’s Recent Revelations on JFK Jr. as a Lover: ‘All I Can Say Is…’
- ’90s Rock Band Extends 2026 Tour With Special Guests
- Sam Bankman-Fried formally files for pardon—but White House reiterates that FTX cofounder’s odds are slim